CVS remains a great Buy here, driven by the raised FY2025 adj EPS guidance and the robust outperformance against its healthcare peers despite the industrywide headwinds. Margin recovery is expected to accelerate from FY2026, supported by the Medicare Advantage four-star ratings, the upcoming ACA exit, and the repricing of group MA contracts. CVS' valuations remain discounted at current levels, with patient investors being paid rich dividend yields pending its upward re-rating.
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS posts a sharper MBR as PDR impacts ease and government business strengthens while maintaining a cautious full-year outlook.
| Health Care Providers & Services Industry | Healthcare Sector | J. David Joyner CEBS CEO | XMUN Exchange | US1266501006 ISIN |
| US Country | 219,000 Employees | 23 Oct 2025 Last Dividend | 7 Jun 2005 Last Split | 17 Dec 1984 IPO Date |
CVS Health Corporation is a leading provider of health solutions in the United States, with a comprehensive portfolio that spans across Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness sectors. As an integral part of the healthcare ecosystem, CVS Health offers a broad range of products and services designed to meet the needs of various stakeholders, including employers, individuals, health plans, and governmental entities. Initially named CVS Caremark Corporation, the company underwent a rebranding to CVS Health Corporation in September 2014, emphasizing its broadened focus on health and wellness. Founded in 1996 and headquartered in Woonsocket, Rhode Island, CVS Health has grown into a cornerstone of the American healthcare industry, continually evolving to address the complex challenges of modern healthcare.
CVS Health Corporation offers a diversified array of healthcare products and services, categorized into three main segments: